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Man has long cherished the warmth, brilliance, and splendor of the sun. In modern American culture,
this attraction has manifested itself in our love for suntanning. One would be hard- pressed to nd an
American who has not daydreamed about sunbathing on a tropical beach. Recent evidence suggests, however,
that our reverie is haunted by harmful radiation from the sun.1 Most obviously, overexposure of the skin
to sunlight causes sunburn, but there are many other adverse eects of solar radiation. Skin exposure
to solar radiation increases the risk of skin cancer, promotes premature aging of the skin (photo aging),
exacerbates photosensitivity diseases, decreases the body's immune response, and interacts adversely with
common drugs.2 Adding to our worries about skin cancer, the incidence of skin cancer increased by a
startling rate during the last decade.3 The annual incidence of carcinoma (generally, a non-fatal skin cancer)
increased from 600,000 people in 1990 to over a million people today; by the year 2000, the lifetime incidence
of melanoma (a potentially fatal skin cancer) is expected to exceed one in 90.4 In deed, the sun may be
leaving an indelible mark not only on the hearts of Americans but also our skin.
Despite this formidable evidence, our love for the sun has not be thwarted. Instead, Americans avidly pursue
means to cope with the dangers of the sun as public awareness of and concern over the risks of skin cancer
1 FDA Commissioner David A. Kessler, M.D., May 11, 1993, (There is overwhelming evidence that exposure to
radiation from the sun is a health hazard.)
2 J. Michael Wentzell, Sunscreens: the ounce of prevention, American Family Physician, Apr. 1, 1996, at
1713; see also 58 Fed. Reg. 28285.
3 Patrick R. Jones, Protecting the Consumer from Getting Burned, 20 American Journal of Law & Medicine
317, 318 (1994).
4 Wentzell, supra note 2.
1and premature skin aging due to exposure to the sun increases.5 This trend explains why there have been
over 150 brands of sunscreens available on the market, with the current market estimated to be worth more
than a half a billion dollars per year.6 It is now well-recognized that proper use of sunscreens will help
prevent the occurrence of skin cancer and premature aging of the skin.7 In fact, many health reports list
sunscreens, second only to avoidance of the sun, as an eective way of dealing with the risks associated with
sun exposure.8
It is important, however, for the public to know that sunscreens are not a panacea for the adverse eects of
solar radiation and that they are not a substitute for avoidance of the sun. Along with the many benets
attributed to sunscreen products, there is also the risk that these products create a false sense of security
among consumers. Consumers have also been susceptible to being misled about the promoted uses and
relative value of sunscreen products. Finally, consumers have not always been well-informed about how and
when such products should be applied. In regulating sunscreen products, the Food & Drug Association
(FDA) has taken up many of these concerns as it seeks to ensure that such products are safe and eective
and not misbranded. Relief and guidance from the FDA have come in the form of the Tentative Final
Monograph (\TFM") for Over-the-Counter (\OTC") Sunscreen Drug Products, a comprehensive regulation
of OTC sunscreen drug products, which, in its nal form, will be codied in 21 C.F.R. x352.
5 T. Carpenter et al, Protection from Sun Protectors, Drug & Cosmetic Industry, March 1, 1996, at 56; see
Jones, supra note 3 at 319.
6 Wentzell, supra note 2; Elif Sinanoglu, Don't Get Burned When Buying Sunblock, Money, July 1994, at
121.
7 Sunscreen Drug Products for Over-the-Counter Human Use; Tentative Final Monograph, 58 Fed. Reg. 28194,
28298 (1993) (to be codied at 21 C.F.R. x 352.52 (e)(6)); for additional sources, see references listed at 58 Fed. Reg.
28194, 28223 (1993) (references 1-18) and 58 Fed. Reg. 28194, 28237 (references 1-11).
8 Paula Kurtzweil, Seven Steps to Safer Tanning, FDA Consumer, June 1, 1996, at 6; Peter H. Rheinstein,
Seven Tips for Sun Sense, American Academy of Family Physicians, Sep. 15, 1996, at 1385.
2This paper rst seeks, in background, to discuss the role of the TFM system in regulating sunscreen
products. It will then both examine two prominent controversies, namely the problem of UVA protection
and the proposed cap on SPF values, and then assess the related deciencies of the current labeling scheme
under the TFM for OTC Sunscreen Drug Products. Finally, the paper will discuss the barriers to more
comprehensive protection in sunscreen products.
Background
Sunscreen: Drug or Cosmetic
Sunscreen products are regulated as drugs by the FDA.9 Products which make protective claims relating to
sun exposure must conform to the TFM requirements.10 The TFM lists the terms which would constitute
such a claim, including sunscreen, sunblock, sunshield, SPF, an SPF value, etc.11 This requirement applies,
typically, to traditional beach products which have active sunscreen ingredients and are intended to prevent
sunburn and protect the skin from the harms of solar radiation. For this reason, such products fall under
the denition of drug in section 201 (g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the \FD&C
Act").12 They are also drugs under section 201 (g)(1)(C) of the FD&C Act because they aect the body's
physiological response to radiation in that they lessen its erythema reaction.13
There are two types of products, however, that present unique problems regarding how they should be
9 58 Fed. Reg. 28194, 28195 (1993); the definitions for drugs and cosmetics are found in section 201 of
the Federal Food, Drug, and Cosmetic Act. See 21 U.S.C. x321 (g), (I).
10 58 Fed. Reg. 28194, 28204-28205 (1993).
11 Id.
12 21 U.S.C. 321 (g)(1)(B); see 58 Fed. Reg. 28194, 28195 (1993).
13 21 U.S.C. 321 (g)(1)(C); see 58 Fed. Reg. 28194, 28195 (1993).
3dened and regulated. The rst group can be described as beach products which do not contain any active
sunscreen ingredients listed in the TFM for OTC Sunscreen Drug Products and which do not make any
therapeutic or protective claims (e.g., suntan lotion). These products are not drugs. However, the FDA is
proposing, under 21 U.S.C. 321 (n), 362 (a), and 371 (a), to amend the cosmetic regulations in 21 C.F.R.
Part 700 so as to require these products to display the following warning: Warning { This product does not
contain a sunscreen and does not protect against sunburn.14 This will ensure that such products are used
safely and will not be confused with sunscreen drug products.
The other highly debated category of sunscreen related products are those which are not traditional beach
products but which contain at least one active sunscreen ingredient listed in the TFM for OTC Sunscreen
Drug Products (e.g., hair spray, nail polish, or lipstick). For these products, which are generally perceived
as cosmetics, the distinction is again based on each product's intended use and how it is represented to the
public. Any product containing sunscreen active ingredients and displaying sunscreen labeling claims is a
drug. Accordingly, the FDA will not regulate these products as drugs under certain circumstances; most
importantly, the term sunscreen must not be used, no SPF value can given, and the ingredient is mentioned
without any protective claims and only by its cosmetic name in the ingredient list.15
There are several reasons why the FDA would want to classify a product as a drug. In general, drug
regulations are more stringent. Features of the FD&C Act that distinguish the regulation of drugs from
that of cosmetics are as follows: a drug must be approved by the FDA as safe and eective for those uses
indicated on its label;16 adverse eects and product-related injuries must be reported to the FDA;17 drugs
and drug manufacturing facilities must be registered with the FDA.18 Additionally, manufacturers of drugs
14 58 Fed. Reg. 28194, 28207 (1993).
15 58 Fed. Reg. 28194, 28205 (1993).
16 21 U.S.C.x321(p), x355.
17 Id., x355.
18 Id., x360.
4must follow current good manufacturing practices under the stricter adulteration standards.19 Finally, the
FDA can preclude the use of certain ingredients.
The OTC drug monograph system
The FDA is dedicated to the task of ensuring the safety and eectiveness of marketed drugs. As part of
this mission, it requires the premarket approval of new drugs through the submission of a new drug applica-
tion (\NDA"). However, NDA premarket approval only pertains to new drugs, and not all drugs fall under
this denition.20 In 1972, the FDA established the OTC drug monograph system for OTC drug review.21
Through this process, the FDA aspired to examine the safety and eectiveness of all OTC drug products
marketed in the United States before 1972 that had not been scrutinized as NDAs, as well all OTC drug
products that had been covered by NDAs but which were marketed before the enactment of the 1962 amend-
ments to the Act which required testing for eectiveness.22 Given the agency's limited resources, the FDA
determined that the OTC drug review would be performed most eciently if OTC drugs were evaluated on
a class rather than individual basis.23
These monographs embody the FDA's comprehensive regulation regarding a class of OTC drug products
(such as sunscreens) and establish the conditions under which such class is generally recognized as safe and
eective and not misbranded, including both the requirement or exclusion of active ingredients, combinations
19 Id., x351.
20 A drug is a new drug if it is not generally recognized as safe and effective for its indicated uses or
if it has not been used to a material extent or for a material time under such conditions (i.e., uses). See
21 U.S.C. x321 (p).
21 Now codified at 21 C.F.R. part 330.
22 Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph
System, Advance Notice of Proposed Rulemaking, 61 Fed. Reg. 51625, 51626 (1996).
23 Id.
5of active ingredients, labeling, etc. When a nal monograph is adopted, it is published under 21 C.F.R. part
330. The regulations are generally not enforced, however, until the nal monograph is published.24
In 1978, the FDA published an advance notice of proposed rulemaking (\ANPR") to establish a monograph
for OTC sunscreen drug products.25 In 1993, the FDA furthered the ANPR with its tentative nal mono-
graph for OTC sunscreen drug products to be codied at 21 C.F.R. part 352.26 The TFM has been followed
by two proposed amendments, but the FDA has not made its determination on a nal monograph for OTC
sunscreen drug products.
Sunscreen Drug Product Labeling Scheme
One of the major goals of the FDA in regulating OTC sunscreen drug products is to ensure that consumers
can reliably identify the amount of protection the sunscreen product provides from exposure to the sun. The
TFM for OTC Sunscreen Drug Products has established labeling requirements to accomplish this end. These
require that traditional sunscreen products provide a sun protection factor value (\SPF") accompanied by its
product category designation (\PCD"), which will describe the product's SPF value as minimal, moderate,
high, very high, or ultra high.27 SPF is dened as the ratio of the amount of energy required to produce
a minimal sunburn through the applied sunscreen to the amount of energy required to produce the same
amount of sunburn without any sunscreen.28 In essence, this means that a person who uses a sunscreen
24 Food & Drug Administration, FDA Compliance Guide, x7132 (b)(15).
25 43 Fed. Reg. 38206 (1978).; for authority, see 21 C.F.R. 330.10 (a) (6).
26 58 Fed. Reg. 28194 (1993).
27 58 Fed. Reg. 28194, 28219 (1993).
28 Id.; 58 Fed. Reg. 28194, 28295 (1993).
6with SPF 2 could remain exposed to the sun twice as long as he ordinarily could before suering minimal
sunburn; a person who uses an SPF 30 could remain exposed thirty times as long. In addition, the FDA
has recommended a Sunscreen Product Guide (\SPG") to appear on the labeling of all such products. The
SPG is intended to allow consumers to ascertain which SPF level is appropriate for their skin type.29 There
are, of course, many problems with the labeling system proposed under the TFM for OTC Sunscreen Drug
Products, including the issues of UVA protection and limitation of SPF values.
The UVA Radiation Problem
Much debate has focused on the need for protection from UVA radiation and the issue of appropriate label-
ing. Ultraviolet (\UV") radiation, which causes most of the adverse eects of solar radiation, ranges between
200 and 400 nm and is divided into three bands: UVC (200 - 290 nm), UVB (290 - 320 nm), and UVA (320
to 400 nm). Of these three types of UV radiation, only UVB and UVA penetrate the earth's atmosphere to
reach the its surface. Because the denition of sunscreen active ingredients pertains directly only to UVB
rays, SPF values do not give a clear indication of protection aorded against UVA rays.30 In fact, the TFM
for OTC Sunscreen Drug Products does not even require sunscreen products to protect against UVA rays.
Originally, experts believed that only UVB caused cancer, and hence sunscreens were formulated only to
protect against UVB.31 The theory was that sunscreens should protect skin from burning (which was then
29 58 Fed. Reg. 28194, 28217 (1993).
30 58 Fed. Reg. 28194, 28295 (1993) (defining active ingredients based on absorption of UV radiation
from 290 to 320 nm).
31 58 Fed. Reg. 28194, 28232 (1993).
7believed to be caused solely by UVB) and to allow tanning from UVA rays.32 Evidence now shows that both
UVA and UVB cause sunburn, premature aging of the skin, skin cancer.33 Although UVA is less harmful
than UVB per dose, the amount of UVA that reaches the earth's surface is vastly greater than that amount
of UVB, and UVA radiation penetrates the skin more eciently than UVB.34 UVA rays may account for
more than 15% of the adverse eect solar radiation has on human skin that is exposed to the sun.35 In deed,
there is no such thing as a risk-free tan.36
The most alarming consequence of the FDA's inability to deal with the issue of UVA radiation is that it
has given sunscreen users a false sense of security. Consumers who rely solely upon SPF values to assess the
eectiveness of a sunscreen product may be inclined to remain exposed to the sun for longer periods of time
as a result of their condence in the product they use. These consumers are thus beguiled into increasing
their exposure to UVA radiation. In some situations, the overall eect could be that the consumer actually
increases his risk of cancer relative to what would have arisen under the more moderate exposure to the sun
that would have occurred had the consumer not been lulled into a false sense of security. Therefore, FDA
must devise a system that promotes the use of broad spectrum sunscreens (i.e., sunscreens that adequately
protect against both UVB and UVA radiation).
The FDA is devising labeling requirements for products that purport to protect skin from UVA radiation in
order to ensure that such products are not misleading and oer adequate UVA protection. The TFM states
that products claiming to protect skin from UVA rays must contain ingredients that protect against UV
32 Id.; see Jones, supra note 3 at 320.
33 58 Fed. Reg. 28194, 28233 (1993); 59 Fed. Reg. 160042, 16043 (1994).
34 Wentzell, supra note 2; 58 Fed. Reg. 28194, 28233 (1993).
35 58 Fed. Reg. 28194, 28233 (1993).
36 See Wentzell, supra note 2; 58 Fed. Reg. 28194, 28288 (1993).
8radiation extending up to 360 nm.37 A sunscreen product that provides protection against UVB and UVA
radiation up to this level of the spectrum (360 nm) may be characterized as a broad spectrum sunscreen.38
However, the FDA has not been able to establish a method for determining UVA protection and has ten-
tatively recommended using a testing method similar to the one suggested by Lowe et al.39 In addition,
although the FDA requires broad spectrum products to protect against UV rays between 290 and 360 nm,
the FDA has not been able to determine which part of the UVA spectrum actually presents signicant health
risk.40 Supported by evidence, the FDA believes that the longer UVA wavelengths (340 to 400 nm) are less
hazardous than the shorter UVA wavelengths (320 to 340 nm).41 The same evidence suggests, however,
that longer wavelength UVA rays can cause both tissue damage and tumors.42 The dening band at 360
nm is a tentative compromise, and even the FDA admits that UVA or broad spectrum labeling could be
misleading.43
SPF Cap Controversy
37 58 Fed. Reg. 28194, 28233 (1993).
38 Id.
39 58 Fed. Reg. 28194, 28250 (1993); 59 Fed. Reg. 16042 (1994); Lowe, N. J. et al., Indoor and Outdoor
Efficacy Testing of a Broad Spectrum Sunscreen Against Ultraviolet A Radiation in Psoralen-sensitized Subjects,
17 Journal of the American Academy of Dermatology 224 (1987).
40 See Discussion of Ultraviolet A-Protection Claims and Testing Procedures for Over-the-Counter Sunscreen
Drug Products, Notice of Public Meeting and Reopening of the Administrative Record, 59 Fed. Reg. 16042 (1994).
41 59 Fed. Reg. 16042 (1994); McKinlay, A.F., and B. L. Diffey, A Reference Action Spectrum for
Ultraviolet Induced Erythema in Human Skin, 6 CIE Journal 17 (1987).
42 F-D-C Reports, The Tan Sheet, May 17, 1993, at 12-14.
43 See Id.
9Another area of reform for sunscreen labeling, which the FDA hopes will ensure safer and more eective
use, has been the proposed cap on SPF values to a level of 30.44 This proposal came as higher SPF values
began to dominate the market.45 According to the FDA, the benets of SPF values above 30 are negligible.
The FDA has accepted evidence that shows a sunscreen product with SPF of 30 blocks 96.7% of the UVB
radiation to which skin would be exposed without any protection; an SPF 40 sunscreen product increases this
level of protection to 97.5% of UVB radiation, and an SPF 70 would block only 98.7 % of UVB radiation.46
The FDA weighs these minimal additional benets against the potential health risks associated with prod-
ucts of SPF values above 30. Chemical ingredients of sunscreen products can cause skin irritation.47 In
addition, higher concentrations of some ingredients could prove toxic.48 The FDA believes that, although
SPF values higher than 15 are necessary for some consumers in some situations, the risk of added ingredients
outweigh the negligible benets of products with SPF values above 30.49
Not all manufacturers of sunscreen products have opposed the FDA's decision to impose this limit; in fact,
some companies have actually supported limiting SPF values.50 These manufacturers believed that a cap
would end the futile race toward higher SPF values, which they claim both mislead consumers about the
marginal benets of these products and, perhaps more crucially, cause them to focus solely on SPF values
without considering the importance of broad spectrum products.51 A cap would thus cause manufacturers
to produce more well-balanced products that oered more UVA protection and less irritation.52
44 58 Fed. Reg. 28194, 28223, 28227 (1993).
45 Jones, supra note 3 at 319; F-D-C Reports, The Tan Sheet, Oct. 18, 1993, at 10-12.
46 58 Fed. Reg. 28194, 28225 (1993).
47 53 Fed. Reg. 28194, 28225 (1993).
48 Id.
49 See 58 Fed. Reg. 28194, 28223, 28227 (1993).
50 F-D-C Reports, The Tan Sheet, Nov. 22, 1993, at 21-22.
51 Id.
52 Id.
10Other manufacturers, however, have protested the FDA's decision to limit SPF values at 30.53 First, higher
SPF values can help compensate for consumers' failure to apply sunscreen products properly.54 In addition,
these manufacturers argue that there is no merit to the FDA's safety concerns regarding SPF values higher
than 30 because the TFM already limits the concentration of active ingredients (either alone or in combina-
tion) to safe levels.55
Upon analyzing the arguments, the FDA's decision to cap SPF values at 30 appears to be unwarranted.
The posited safety concerns seem dubious. First, despite the FDA's assessment that 30 was an appropriate
break, it still proposed a warning consumers to discontinue use if adverse eects, such as skin irritation,
were to occur.56 Obviously, then, the safety concerns for products with SPF values above 30 also exist for
products with SPF values of 30 and below. The FDA could allow higher SPF values and require the same
safety warning.
The counter-argument is that the risk from added active ingredients in products with SPF greater than 30
outweigh the benets of added protection.57However, this proposition requires the assumption that higher
SPF values require higher concentrations of active ingredients. Oddly, however, the FDA rejected this no-
tion when it earlier justied SPF values above 15.58 Finally, as already mentioned, the TFM sets maximum
concentration levels for the safe and eective use of active ingredients in sunscreen products.59 Surely the
53 F-D-C Reports, The Tan Sheet, Feb. 21, 1994, at 10-11.
54 Id.
55 See 58 Fed. Reg. 28194, 28295 (1993) (to be codied at 21 C.F.R. x352.10, x352.20).
56 58 Fed. Reg. 28194, 28227 (1993).
57 58 Fed. Reg. 28194, 28227 (1993); Wentzell, supra note 2.
58 58 Fed. Reg. 28194, 28226 (1993) (The agency agrees that advances in formulation technology have
allowed manufacturers to develop products with relatively low levels of sunscreen active ingredients and still
achieve high SPF values. The agency is aware of studies demonstrating the importance of the vehicle on the
final performance of a sunscreen product. There is a lack of data showing a significant relationship between
sunscreen ingredient concentration and the final SPF of a product.... The study demonstrated that formulation
and vehicle design have a profound effect on SPF values.)
59 See 58 Fed. Reg. 28194, 28295 (1993) (to be codied at 21 C.F.R. x352.10, x352.20).
11FDA does not doubt the safety of these concentration limits.
The FDA's actual motivation in setting the SPF limit must therefore be based on the FDA's desire to keep
prices of sunscreen products down and to eliminate consumer misperceptions that are caused by higher
SPF values. A cap on SPF values will bring the manufacturers' race for higher SPF values to an end and,
therefore, stabilize sunscreen prices.60 Although the goal might be to give people a greater opportunity
to purchase sunscreen products by promoting aordable prices and, thus, ensuring that more people used
sunscreens, the policy is paternalistic and grossly interferes with consumer autonomy.
Secondly, the policy does not eectively respond to problems concerning public misperception. For example,
even if the FDA believes that the public's xation on SPF values has caused consumers to overlook the need
for UVA protection, a cap on SPF values does not inherently correlate with the promotion of broad spectrum
products. Therefore, rather than limitations on SPF values, the public needs a more explicit promotion of
broad spectrum products.
Lastly, the FDA's agenda could simply be to clarify the public's understanding of SPF values; for most
consumers do not understand the problem of diminishing returns on the benets of SPF values above 30.
Nevertheless, the FDA's labeling system under the TFM for OTC Sunscreen Drug Products is inherently
susceptible to consumer error in that it depends upon consumers' ability to accurately evaluate their skin
type in relation to the SPG.61 A more appropriate way of avoiding consumer confusion would be for the
FDA to adopt more accurate descriptions for the PCD and SPG, such as those suggested by the American
Academy of Dermatology.62
60 F-D-C Reports, The Tan Sheet, Nov. 22, 1993, at 21-22.
61 See 58 Fed. Reg. 28194, 28217 (1993).
62 F-D-C Reports, The Tan Sheet, Apr. 18, 1994, at 21 (recommending the following PCD changes: minimal
(SPF 4-8), moderate (SPF 8-12), and good (SPF 15)).
12Promoting More Comprehensive Protection
From these regulatory proposals concerning SPF values and broad spectrum sunscreens, it is apparent that
the FDA wishes to promote more comprehensive and eective sunscreens protection while ensuring that
these products do not pose any unnecessary risk of adverse skin reaction. The FDA must reconsider many
of its policies, however, if it is to accomplish this task. One approach that requires further consideration and
development is the use of physical sunscreens (i.e., blockers) which reect or scatter UV radiation. Sunscreen
ingredients are generally classied as either chemical (organic) or physical (inorganic).63 Functionally, these
two categories are fundamentally dierent in that chemical sunscreen ingredients absorb UV radiation, while
physical sunscreen ingredients reect or scatter UV radiation.64 Each type also has its unique advantages
and disadvantages. Most notably, high levels of organic ingredients in sunscreen products can cause sensitiza-
tion and irritation of skin; inorganic ingredients, however, have far less potential for adverse skin reaction.65
Physical sunscreens also generally protect against a broader spectrum of UV radiation, including UVA.66
Unlike chemical sunscreen ingredients, however, physical sunscreens are not invisible after application and
oer little water resistance.67
The most critical problem with physical sunscreen ingredients is that they tend to clump when heated.68
63 Discussion of the Photochemistry and Photobiology of Sunscreens, Public Meeting and Reopening of the
Administrative Record, 61 Fed.Reg. 42398, 42399 (1996); Wentzell, supra note 2.
64 Id.
65 Wentzell, supra note 2; Carpenter et al, Protection from Sun Protectors, Drug & Cosmetic Industry,
Mar. 1, 1996, at 56; O'Lenick et al., Dimethicone copolyop phosphate: an additive that increases SPF,
Soap-Cosmetic-Chemical Specialties, May 1, 1996, at 54.
66 Wentzell, supra note 2.
67 Id.; Carpenter, supra note 5.
68 Carpenter supra note 5, ; O'Lenick, supra note 2.
13This makes it dicult to maintain high SPF values with physical sunscreens and can result in undesired
aesthetic results.69 To deal with this problem, manufacturers disperse physical sunscreen ingredients within
the formulation, which in general are organic.70 In order to aord eective protection, the physical sunscreen
must remain properly dispersed in the formula.71 Available formulation vehicles include sprays, gels, and
emollient bases; most popular is the oil-in-water emulsion.72
Another approach completely circumvents the dispersal of physical sunscreens and simply seeks to reduce
organic contact with the skin. This can be achieved either by encapsulation strategies, which unfortunately
can be very expensive, or through the use of polymers, which x organic actives to the outer layers of the
skin.73 This results in less skin irritation.
Before manufacturers can explore these opportunities, there are several regulatory impediments that the
FDA must remove. First, the FDA's denition of active sunscreen ingredient is remarkably incomplete.
The TFM for OTC Sunscreen Drug Products denes sunscreen active ingredients with by focusing on the
absorption of UV radiation.74 The denition does not consider an ingredients ability to scatter or reect UV
radiation. This denition excludes some sunscreen ingredients which are highly eective. Most obviously,
the denition does not include physical sunscreen ingredients, because they reect and scatter UV radiation
rather than absorb. The FDA has recognized that the denition of active ingredients needs to be modied
to incorporate the ingredients that amply absorb, reect, or scatter UV radiation.75
69 Wentzell, supra note 2; Carpenter, supra note 5; O'Lenick, supra note 58.
70 Carpenter, supra note 5; O'Lenick, supra note 58.
71 Carpenter, supra note 5; O'Lenick, supra note 58; Wentzell, supra note 2.
72 Wentzell, supra note 2; O'Lenick, supra note 58.
73 Carpenter, supra note 5.
74 58 Fed. Reg. 28194, 28295 (1993) (to be codified at 21 C.F.R. x352.3) (Sunscreen active ingredient.
An active ingredient that absorbs at least 85 percent of the radiation in the UV range at wavelengths from
290 to 320 nanometers, but may or may not transmit radiation at wavelengths longer than 320 nanometers.)
(emphasis added).
75 Sunscreen Drug Products for Over-the-Counter Human Use; Amendment to the Tentative Final Monograph, 61
14Another hurdle which should be eliminated is the minimum dosage requirements for permitted combinations
of active ingredients in sunscreen products. The FDA's objective is to ensure that each ingredient used
contributes signicantly to the overall eectiveness of the product when combinations are used.76 However,
the FDA admits that it is unaware of any method for determining each ingredient's contribution to the
eectiveness of a combination sunscreen product.77 Therefore, the minimum concentration levels established
are inherently arbitrary and conict with the FDA's general position of promoting the lowest eective dose
of active drug ingredients.78
Because minimum concentration requirements discourage manufacturers from creating innovative formula-
tions, which would lower the risk of adverse reaction, the FDA should rely upon total product performance
in determining eectiveness of a particular ingredients concentration level. This should be gauged by SPF
testing and an appropriate test for UVA protection. The need for more innovative products outweighs the
FDA's concern that consumers will be duped into purchasing these products based on the inclusion of a par-
ticular ingredient or combination. First, there is no evidence to show that consumers rely upon ingredient
listing more so than SPF values in determining which product to buy. Moreover, the FDA has not estab-
lished a relationship between the minimum concentration requirements and an ingredient's eectiveness in
a particular combination; therefore, the FDA cannot determine whether consumers are being mislead about
a particular ingredient's contribution to the eectiveness of a combination sunscreen product.
Fed. Reg. 48645, 48646 (1996).
76 58 Fed. Reg. 28194, 28214 (1993). Note that safety considerations are not relevant to this debate
because it is well recognized that the FDA establishes maximum concentration levels active ingredients, both
alone and in combination, which ensures the safety of such products. Id., at 28295-28296 (to be codified at
21 C.F.R. xx352.10, 352.20.
77 Id.
78 F-D-C Reports, The Tan Sheet, Oct. 28, 1996, at 11-12.
15The nal barrier is the diculty of getting products approved of as safe and eective for a particular use
and thus included in the sunscreen monograph. For example, until recently, only one physical sunscreen
ingredient was approved by the FDA in the TFM for OTC Sunscreen Drug Products.79 The plan to propose
an amendment to the sunscreen drug products tentative nal monograph to include zinc oxide as an active
ingredient will have a profound eect on the FDA's denition of sunblock.80 It has taken many years, how-
ever, to have zinc oxide included in the sunscreen drug product tentative nal monograph.
Currently, there are two pertinent ways for drugs to attain OTC status: through the NDA process and
through the monograph procedure.81 The NDA process is very costly (requiring clinical studies, reporting
of post-market adverse reactions, etc).82 In most circumstances, there is not enough economic incentive for
a manufacturer to undergo the NDA process; thus, in most situations, a manufacturer would simply prefer
to have a OTC drug approved under the monograph system.83
To avoid NDA approval requirements, the product must not be a new drug as dened by section 201 (p)
of the FD&C Act.84 Thus, the product must be generally recognized as safe and eective for its labeled
conditions and must have been used to a material extent and for a material time under such conditions.85
79 Compare 58 Fed. Reg. 28194, 28240 (1993) (requiring a product to contain titanium dioxide to be labeled a sunblock,
which must also reect or scatter UV rays and have an SPF of at least 12) and 61 Fed. Reg. 42398, 42399 (1996) (maintaining
titanium dioxides status as safe and eective sunblock ingredient but denying zinc oxide such status under Category I) with
F-D-C Reports, The Tan Sheet, Nov. 25, 1996, at 8-9 (reporting the FDA's conclusion to confer zinc oxide Category I status
after sucient evidence demonstrated that zinc oxide safely and eectively blocks UV radiation in both the UVB and UVA
wavelengths).
80 Compare 58 Fed. Reg. 28194, 28240 (1993) (establishing the requirements of a product labeled sunblock) and Id.,
28295 (dening sunscreen opaque sunblock) with Cynthia Robins, Common Sense Skin Care Fashion Thursday, San Francisco
Examiner, May 9, 1996 (quoting Dr. Mark Mitchnick, medical director of SunSmart, who asserts, although prematurely, that
a sunblock must have an SPF of 12 and contain a physical sunscreen like zinc oxide).
81 61 Fed. Reg. 51625, 51629 (1996); See Stephen P. Mahinka, Esq. and Elizabeth Bierman, Esq.,
Direct-to-OTC Marketing of Drugs: Possible Approaches, 50 Food & Drug L.J. 49 (1995).
82 Id.
83 For a detailed discussion on the relative advantages and disadvantages of both the NDA and monograph
process, see Mahinka and Bierman, supra note 74. See also, Greff at 250-251.
84 21 U.S.C. 321 (p); 61 Fed. Reg. 51625, 51626 (1996).
85 Id.
16The greatest diculty is that the FDA has interpreted the marketing requirements of section 201 (p) (i.e.,
used to a material extent and for a material time) to mean marketing in the United States.86 Although
foreign marketing data has been utilized as additional information by the FDA, the agency takes the position
that the marketing of an OTC drug in a foreign country, but never the United States, does not satisfy [the
marketing requirements].87
This strict policy unnecessarily delays the use of many potential sunscreen ingredients and prevents manu-
facturers from developing more comprehensive sunscreen products. For example, the policy was a signicant
issue in the attempted promotion of Parsol 1789 (avobenzone) as an active sunscreen ingredient. Parsol 1789
was nally approved for certain conditions in the TFM for OTC Sunscreen Drug Product.88 This occurred
only after there was sucient U.S. marketing data from two avobenzone containing products, Schering-
Plough's Shade UVAGuard and Herbert's Photoplex, which had received NDA approval.89 However, be-
cause manufacturers will not sustain the costs of the NDA process for all potential sunscreen ingredients,
many potential sunscreen ingredients (for which there is only foreign market data to demonstrate their safety
and eectiveness) are not included in the TFM for OTC Sunscreen Drug Products and will remain out of
sunscreen drug products.
Recently, the FDA gave an advance notice of proposed rulemaking to amend its regulations and accept
foreign marketing data alone as sucient for consideration of additional conditions (i.e., active ingredients,
indications, dosage form, dosage strength, route of administration, active ingredient combination, or any
combination of these conditions) in the OTC drug monograph system.90
The FDA is focusing on three basic issues: the nature of the marketing or use, the amount of marketing
86 61 Fed. Reg. 51625, 51626 (1996).
87 Id. at 51627.
88 61 Fed. Reg. 48645 (1996).
89 Id., at 48646.
90 61 Fed. Reg. 51625, 51627 (1996).
17time, and the extent of distribution and use in marketing. The rst issue inquires which countries should be
accepted, what type of adverse eect reporting system should be required, and the type of drug administration
which should be considered (i.e., whether the product was marketed by prescription, through pharmacists,
OTC, etc).91 The second issue questions what amount of marketing time qualies as material time. The FDA
is proposing a minimum of ve years of marketing.92 The nal issue questions what extent of distribution
and use qualies as for a material extent.93
Overall, in reevaluating the value of foreign marketing data as an exclusive source of approval for additional
drug conditions in the OTC drug monograph system, it appears that the FDA is mostly concerned with
safety risks. It wants data sucient for conrming the safeness of a potential OTC drug condition. The
establishment of new eligibility criteria will have a tremendous impact on the production of sunscreens, and
the sooner the FDA resolves these issues, the sooner more comprehensive sunscreen products will become
available to American consumers.
91 Id.
92 Id., at 51629.
93 Id.
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